A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Risankizumab
DRUG: Risankizumab
DRUG: Vedolizumab

Sponsor

AbbVie